These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 18765540

  • 1. Effective CpG immunotherapy of breast carcinoma prevents but fails to eradicate established brain metastasis.
    Xiong Z, Gharagozlou S, Vengco I, Chen W, Ohlfest JR.
    Clin Cancer Res; 2008 Sep 01; 14(17):5484-93. PubMed ID: 18765540
    [Abstract] [Full Text] [Related]

  • 2. Potentiation of a dendritic cell vaccine for murine renal cell carcinoma by CpG oligonucleotides.
    Chagnon F, Tanguay S, Ozdal OL, Guan M, Ozen ZZ, Ripeau JS, Chevrette M, Elhilali MM, Thompson-Snipes LA.
    Clin Cancer Res; 2005 Feb 01; 11(3):1302-11. PubMed ID: 15709202
    [Abstract] [Full Text] [Related]

  • 3. Activation of tumor-specific CD8+ T Cells after intratumoral Ad5-TRAIL/CpG oligodeoxynucleotide combination therapy.
    VanOosten RL, Griffith TS.
    Cancer Res; 2007 Dec 15; 67(24):11980-90. PubMed ID: 18089829
    [Abstract] [Full Text] [Related]

  • 4. An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen.
    Wakita D, Chamoto K, Zhang Y, Narita Y, Noguchi D, Ohnishi H, Iguchi T, Sakai T, Ikeda H, Nishimura T.
    Int Immunol; 2006 Mar 15; 18(3):425-34. PubMed ID: 16415100
    [Abstract] [Full Text] [Related]

  • 5. CpG-ODN-based immunotherapy is effective in controlling the growth of metastasized tumor cells.
    Kim HA, Ko HM, Ju HW, Kim KJ, Roh SG, Lee HK, Im SY.
    Cancer Lett; 2009 Feb 08; 274(1):160-4. PubMed ID: 18952369
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Immuno-viral therapy of brain tumors by combination of viral therapy with cancer vaccination using a replication-conditional HSV.
    Toda M, Iizuka Y, Kawase T, Uyemura K, Kawakami Y.
    Cancer Gene Ther; 2002 Apr 08; 9(4):356-64. PubMed ID: 11960286
    [Abstract] [Full Text] [Related]

  • 10. CpG oligodeoxynucleotide-induced immunity prevents growth of germinal center-derived B lymphoma cells.
    Ponzio NM, Cutro S, Hu J, Marzouk A, Marshall JD.
    Int Immunopharmacol; 2006 Dec 20; 6(13-14):2057-68. PubMed ID: 17161362
    [Abstract] [Full Text] [Related]

  • 11. Combined dendritic cell- and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy.
    Heckelsmiller K, Beck S, Rall K, Sipos B, Schlamp A, Tuma E, Rothenfusser S, Endres S, Hartmann G.
    Eur J Immunol; 2002 Nov 20; 32(11):3235-45. PubMed ID: 12555669
    [Abstract] [Full Text] [Related]

  • 12. Cancer immunotherapeutic effects of novel CpG ODN in murine tumor model.
    Cho HC, Kim BH, Kim K, Park JY, Chang JH, Kim SK.
    Int Immunopharmacol; 2008 Oct 20; 8(10):1401-7. PubMed ID: 18687302
    [Abstract] [Full Text] [Related]

  • 13. Cell therapy with preimmunized effector cells mismatched for minor histocompatible antigens in the treatment of a murine mammary carcinoma.
    Morecki S, Yacovlev E, Gelfand Y, Uzi I, Slavin S.
    J Immunother; 2001 Oct 20; 24(2):114-21. PubMed ID: 11265768
    [Abstract] [Full Text] [Related]

  • 14. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity.
    Mangsbo SM, Ninalga C, Essand M, Loskog A, Tötterman TH.
    J Immunother; 2008 Jan 20; 31(1):34-42. PubMed ID: 18157010
    [Abstract] [Full Text] [Related]

  • 15. [Therapeutic and immunological effects of microwave ablation combined with CpG ODN on transplanted colon carcinoma in mice].
    Zou N, Li XF, Ding WM, Lai QH, Zhang JR.
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 May 20; 30(5):984-8. PubMed ID: 20501375
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. In vitro and in vivo effects of CpG-Oligodeoxynucleotides (CpG-ODN) on murine transitional cell carcinoma and on the native murine urinary bladder wall.
    Olbert PJ, Schrader AJ, Simon C, Dalpke A, Barth P, Hofmann R, Hegele A.
    Anticancer Res; 2009 Jun 20; 29(6):2067-76. PubMed ID: 19528466
    [Abstract] [Full Text] [Related]

  • 18. Screening of novel immunostimulatory CpG ODNs and their anti-leukemic effects as immunoadjuvants of tumor vaccines in murine acute lymphoblastic leukemia.
    Wang J, Zhang W, He A, Zhao W, Cao X.
    Oncol Rep; 2011 Feb 20; 25(2):519-29. PubMed ID: 21165566
    [Abstract] [Full Text] [Related]

  • 19. Implication of macrophages in tumor rejection induced by CpG-oligodeoxynucleotides without antigen.
    Auf G, Carpentier AF, Chen L, Le Clanche C, Delattre JY.
    Clin Cancer Res; 2001 Nov 20; 7(11):3540-3. PubMed ID: 11705874
    [Abstract] [Full Text] [Related]

  • 20. Adoptive immunotherapy of breast cancer with lymph node cells primed by cryoablation of the primary tumor.
    Sabel MS, Arora A, Su G, Chang AE.
    Cryobiology; 2006 Dec 20; 53(3):360-6. PubMed ID: 16973145
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.